AB&B Bio-Tech Co. Ltd. JS Reports 919% Surge in Revenue to RMB 71.1 Million for H1 2025, Narrows Loss to RMB 121.5 Million, EPS at RMB (0.34)

Reuters

2025/08/28

AB&B Bio-Tech Co. Ltd. JS Reports 919% Surge in Revenue to RMB 71.1 Million for H1 2025, Narrows Loss to RMB 121.5 Million, EPS at RMB (0.34)

AB&B Bio-Tech Co. Ltd. JS has announced its unaudited interim results for the six months ended June 30, 2025. The company reported a significant increase in revenue, which rose from RMB7.0 million in the first half of 2024 to RMB71.1 million in the same period of 2025. This increase is attributed to higher sales of quadrivalent subunit influenza vaccines and adjustments made to the estimated sales return for 2024. The cost of sales decreased by 18.3%, from RMB12.6 million in 2024 to RMB10.3 million in 2025, aligning with enhanced inventory management. Consequently, the company achieved a gross profit of RMB60.8 million, a significant turnaround from the gross loss of RMB5.6 million reported in 2024. However, the loss for the period was RMB121.5 million, compared to RMB155.8 million in the previous year. Founded in 2015, AB&B Bio-Tech is a China-based vaccine company focused on the research, development, manufacturing, and commercialization of innovative and traditional vaccines using new technical methods.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AB&B Bio-Tech Co. Ltd. JS published the original content used to generate this news brief on August 28, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2562708950"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2562708950\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2562708950?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-28 16:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2562708950","market":"nz","top_or_hot":-1,"title":"AB&B Bio-Tech Co. Ltd. JS Reports 919% Surge in Revenue to RMB 71.1 Million for H1 2025, Narrows Loss to RMB 121.5 Million, EPS at RMB (0.34)","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      AB&amp;B Bio-Tech Co. Ltd. JS Reports 919% Surge in Revenue to RMB 71.1 Million for H1 2025, Narrows Loss to RMB 121.5 Million, EPS at RMB (0.34)\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        AB&amp;B Bio-Tech Co. Ltd. JS has announced its unaudited interim results for the six months ended June 30, 2025. The company reported a significant increase in revenue, which rose from RMB7.0 million in the first half of 2024 to RMB71.1 million in the same period of 2025. This increase is attributed to higher sales of quadrivalent subunit influenza vaccines and adjustments made to the estimated sales return for 2024. The cost of sales decreased by 18.3%, from RMB12.6 million in 2024 to RMB10.3 million in 2025, aligning with enhanced inventory management. Consequently, the company achieved a gross profit of RMB60.8 million, a significant turnaround from the gross loss of RMB5.6 million reported in 2024. However, the loss for the period was RMB121.5 million, compared to RMB155.8 million in the previous year. Founded in 2015, AB&amp;B Bio-Tech is a China-based vaccine company focused on the research, development, manufacturing, and commercialization of innovative and traditional vaccines using new technical methods.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AB&amp;B Bio-Tech Co. Ltd. JS published the original content used to generate this news brief on August 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AB&B Bio-Tech Co. Ltd. JS Reports 919% Surge in Revenue to RMB 71.1 Million for H1 2025, Narrows Loss to RMB 121.5 Million, EPS at RMB (0.34)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAB&B Bio-Tech Co. Ltd. JS Reports 919% Surge in Revenue to RMB 71.1 Million for H1 2025, Narrows Loss to RMB 121.5 Million, EPS at RMB (0.34)\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-08-28 16:35</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      AB&amp;B Bio-Tech Co. Ltd. JS Reports 919% Surge in Revenue to RMB 71.1 Million for H1 2025, Narrows Loss to RMB 121.5 Million, EPS at RMB (0.34)\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        AB&amp;B Bio-Tech Co. Ltd. JS has announced its unaudited interim results for the six months ended June 30, 2025. The company reported a significant increase in revenue, which rose from RMB7.0 million in the first half of 2024 to RMB71.1 million in the same period of 2025. This increase is attributed to higher sales of quadrivalent subunit influenza vaccines and adjustments made to the estimated sales return for 2024. The cost of sales decreased by 18.3%, from RMB12.6 million in 2024 to RMB10.3 million in 2025, aligning with enhanced inventory management. Consequently, the company achieved a gross profit of RMB60.8 million, a significant turnaround from the gross loss of RMB5.6 million reported in 2024. However, the loss for the period was RMB121.5 million, compared to RMB155.8 million in the previous year. Founded in 2015, AB&amp;B Bio-Tech is a China-based vaccine company focused on the research, development, manufacturing, and commercialization of innovative and traditional vaccines using new technical methods.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AB&amp;B Bio-Tech Co. Ltd. JS published the original content used to generate this news brief on August 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02627","symbol_name":"中慧生物-B","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250828:nNDL6YSTmH:1","article_id":"2562708950","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2562708950","pubTimestamp":1756370147,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"AB&B Bio-Tech Co. Ltd. JS Reports 919% Surge in Revenue to RMB 71.1 Million for H1 2025, Narrows Loss to RMB 121.5 Million, EPS at RMB . Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AB&B Bio-Tech Co. Ltd. JS published the original content used to generate this news brief on August 28, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"02627":"中慧生物-B"},"translate_title":"AB&B Bio-Tech Co.Ltd.JS报告2025年上半年收入增长919%至人民币7,110万元，亏损收窄至人民币1.215亿元，每股收益为人民币(0.34)","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02627":0.9},"content_text":"AB&B Bio-Tech Co. Ltd. JS Reports 919% Surge in Revenue to RMB 71.1 Million for H1 2025, Narrows Loss to RMB 121.5 Million, EPS at RMB (0.34)\n    \n\n        AB&B Bio-Tech Co. Ltd. JS has announced its unaudited interim results for the six months ended June 30, 2025. The company reported a significant increase in revenue, which rose from RMB7.0 million in the first half of 2024 to RMB71.1 million in the same period of 2025. This increase is attributed to higher sales of quadrivalent subunit influenza vaccines and adjustments made to the estimated sales return for 2024. The cost of sales decreased by 18.3%, from RMB12.6 million in 2024 to RMB10.3 million in 2025, aligning with enhanced inventory management. Consequently, the company achieved a gross profit of RMB60.8 million, a significant turnaround from the gross loss of RMB5.6 million reported in 2024. However, the loss for the period was RMB121.5 million, compared to RMB155.8 million in the previous year. Founded in 2015, AB&B Bio-Tech is a China-based vaccine company focused on the research, development, manufacturing, and commercialization of innovative and traditional vaccines using new technical methods.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AB&B Bio-Tech Co. Ltd. JS published the original content used to generate this news brief on August 28, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}